Literature DB >> 22160246

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide.

A Faurschou1, F K Knop, J P Thyssen, C Zachariae, L Skov, T Vilsbøll.   

Abstract

A 59-year old man with moderate and stable psoriasis through 15 years was admitted to our Department with inadequately controlled type 2 diabetes. Treatment was initiated with the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide. The patient experienced marked improvement in his psoriasis immediately after the start of liraglutide treatment. Itching stopped within days, scaling was reduced and spots of normal skin emerged. After 3 months, psoriasis was still improving. Excellent glycaemic control and a weight loss of approximately 8 kg over 3 months were moreover obtained. The patient had previously been well controlled in his diabetes without improvement in psoriasis, and the effect of liraglutide on psoriasis started before weight loss occurred. We discuss the possibility of a direct anti-inflammatory effect of liraglutide in psoriasis as well as indirect effects through improvement in comorbidities such as overweight. Randomized clinical trials are needed to reveal whether GLP-1R agonists represent a new therapeutic option for psoriasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22160246     DOI: 10.1007/s00592-011-0359-9

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  8 in total

Review 1.  Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis.

Authors:  Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-04       Impact factor: 3.565

Review 2.  Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time.

Authors:  Eva Klara Merzel Šabović; Mateja Starbek Zorko; Miodrag Janić
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

Review 3.  GLP-1: benefits beyond pancreas.

Authors:  G Muscogiuri; A Cignarelli; F Giorgino; F Prodam; F Prodram; D Santi; G Tirabassi; G Balercia; R Modica; A Faggiano; A Colao
Journal:  J Endocrinol Invest       Date:  2014-08-09       Impact factor: 4.256

Review 4.  Psoriasis and Cardiovascular Risk: A Comprehensive Review.

Authors:  Walter Masson; Martín Lobo; Graciela Molinero
Journal:  Adv Ther       Date:  2020-04-20       Impact factor: 3.845

5.  Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor.

Authors:  Anna K O Rode; Terkild Brink Buus; Veronika Mraz; Fatima Abdul Hassan Al-Jaberi; Daniel Villalba Lopez; Shayne L Ford; Stephanie Hennen; Ina Primon Eliasen; Ib Vestergaard Klewe; Leila Gharehdaghi; Adrian Dragan; Mette M Rosenkilde; Anders Woetmann; Lone Skov; Niels Ødum; Charlotte M Bonefeld; Martin Kongsbak-Wismann; Carsten Geisler
Journal:  Cells       Date:  2022-08-19       Impact factor: 7.666

6.  Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.

Authors:  Maeve Lynch; Tomás B Ahern; Irene Timoney; Cheryl Sweeney; Genevieve Kelly; Rosalind Hughes; Anne-Marie Tobin; Donal O'Shea; Brian Kirby
Journal:  Trials       Date:  2016-01-15       Impact factor: 2.279

Review 7.  Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.

Authors:  Young-Sun Lee; Hee-Sook Jun
Journal:  Mediators Inflamm       Date:  2016-03-24       Impact factor: 4.711

Review 8.  The Microbiotic Highway to Health-New Perspective on Food Structure, Gut Microbiota, and Host Inflammation.

Authors:  Nina Wærling Hansen; Anette Sams
Journal:  Nutrients       Date:  2018-10-30       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.